Table 5.
EORTC QLQ-C30 evaluation of RFA study group.
| Test 1 (before first RFA) | Test 2 (follow-up) | Test 3 (before second RFA) | Test 4 (follow-up) | Test 5 (before third RFA) | Test 6 (follow-up) | |
|---|---|---|---|---|---|---|
| Functional scales | ||||||
| Physical | 24 ± 6 | 24 ± 6 | 25 ± 7 | 28 ± 11 | 24 ± 8 | 29 ± 16 |
| Role | 24 ± 10 | 26 ± 8 | 20 ± 0,0 | 28 ± 10 | 25 ± 7 | 33 ± 11 |
| Emotional | 25 ± 5 | 25 ± 7 | 23 ± 7 | 24 ± 12 | 25 ± 4 | 31 ± 12 |
| Cognitive | 18 ± 8 | 18 ± 9 | 18 ± 8 | 22 ± 13 | 15 ± 7 | 25 ± 21 |
| Social | 28 ± 3 | 24 ± 9 | 27 ± 13 | 22 ± 8 | 20 ± 7 | 30 ± 14 |
| Global quality of life | 43 ± 13 | 35 ± 16 | 28 ± 10 | 28 ± 8 | 33 ± 4 | 28 ± 25 |
| Symptom scales | ||||||
| Fatigue | 27 ± 4 | 28 ± 7 | 28 ± 7 | 28 ± 7 | 28 ± 2 | 32 ± 12 |
| Nausea and vomiting | 13 ± 4 | 13 ± 4 | 13 ± 6 | 12 ± 3 | 15 ± 0 | 25 ± 14 |
| Pain | 22 ± 7 | 23 ± 5 | 28 ± 3 | 27 ± 6 | 15 ± 7 | 33 ± 4 |
| Dyspnea | 18 ± 10 | 20 ± 9 | 20 ± 10 | 20 ± 17 | 10 ± 0 | 25 ± 21 |
| Diarrhea | 12 ± 4 | 12 ± 4 | 13 ± 6 | 10 ± 0 | 15 ± 7 | 20 ± 14 |
| Sleep disturbance | 32 ± 8 | 33 ± 8 | 20 ± 10 | 17 ± 12 | 25 ± 21 | 30 ± 14 |
| Loss of appetite | 23 ± 10 | 23 ± 10 | 27 ± 15 | 20 ± 10 | 15 ± 7 | 25 ± 21 |
| Obstipation | 10 ± 0 | 17 ± 8 | 13 ± 6 | 10 ± 0 | 20 ± 14 | 25 ± 21 |
| Financial burden | 17 ± 8 | 18 ± 8 | 20 ± 14 | 16.6 ± 12 | 20 ± 14 | 25 ± 21 |
High values regarding the function scales are to be rated as a high measure of operability; small values concerning the symptoms, however, speak for a low development of these symptoms.
RFA: radiofrequency ablation; EORTC: European Organisation for Research and Treatment of Cancer; QLQ-C30: Quality of Life Questionnaire-Core 30.